Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBITDA: 2013-2024

Historic EBITDA for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to -$24.2 million.

  • vTv Therapeutics' EBITDA fell 64.45% to -$10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.8 million, marking a year-over-year decrease of 24.26%. This contributed to the annual value of -$24.2 million for FY2024, which is 5.18% up from last year.
  • Latest data reveals that vTv Therapeutics reported EBITDA of -$24.2 million as of FY2024, which was up 5.18% from -$25.5 million recorded in FY2023.
  • Over the past 5 years, vTv Therapeutics' EBITDA peaked at -$11.9 million during FY2020, and registered a low of -$25.5 million during FY2023.
  • Moreover, its 3-year median value for EBITDA was -$24.2 million (2024), whereas its average is -$24.1 million.
  • In the last 5 years, vTv Therapeutics' EBITDA soared by 43.27% in 2020 and then plummeted by 82.77% in 2021.
  • vTv Therapeutics' EBITDA (Yearly) stood at -$11.9 million in 2020, then plummeted by 82.77% to -$21.7 million in 2021, then dropped by 4.05% to -$22.5 million in 2022, then fell by 13.14% to -$25.5 million in 2023, then climbed by 5.18% to -$24.2 million in 2024.